(Pharmaceuticals 2025 review et al., 2025-09-28: 2025 review of ivermectin as an anticancer candidate covering chemistry, mechanisms (WNT/beta-catenin, PI3K/Akt/mTOR, STAT3) and preclinical tumour models, while stating that in vitro active concentrations exceed achievable human plasma levels.
Nonetheless, the disparity between effective in vitro concentrations and achievable plasma levels in humans underscores the need for translational research.
n/a (HTML full text)
(Pharmaceuticals 2025 review et al., 2025-09-28: 2025 review of ivermectin as an anticancer candidate covering chemistry, mechanisms (WNT/beta-catenin, PI3K/Akt/mTOR, STAT3) and preclinical tumour models, while stating that in vitro active concentrations exceed achievable human plasma levels. Study type: narrative review. N: not stated. Country: Ecuador (Universidad Tecnica Particular de Loja). Dose/route/schedule: n/a. Funder/COI: see PubMed record 41155573 (declared none). Comparator: n/a. This review is one of the 2022-2026 reviews requested and is recorded as PARTLY SUPPORTS because it states the exposure gap explicitly. Study type: review.
